Form 4: Camp4 Therapeutics Director Paula Ragan Granted 9,000 Stock Options

Camp4 Therapeutics Corp director Paula Ragan was granted 9,000 stock options with an exercise price of $1.56, vesting on the earlier of the first anniversary of the grant date or the next annual meeting, subject to continued service.

Summary

• Paula Ragan, a Director of Camp4 Therapeutics Corp (CAMP), was granted 9,000 stock options.
• The options have an exercise price of $1.56 per share.
• The grant date for these options was June 25, 2025.
• The options are set to expire on June 24, 2035.
• The shares underlying the option will vest in their entirety on the earlier of the first anniversary of the grant date (June 25, 2026) or the date of the issuer's next annual meeting of stockholders.
• Vesting is contingent upon Ms. Ragan's continued service to the issuer's board of directors through the applicable vesting date.
• Following this transaction, Ms. Ragan beneficially owns 9,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The Form 4 reports a routine grant of stock options to a director, which is a common compensation practice aimed at aligning director interests with shareholder value. It does not contain any negative or significantly positive operational news, but the grant itself is a positive signal of continued commitment.

Positives

• The granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The options have a long expiration date (June 24, 2035), providing ample time for potential value appreciation.

Risks

• Vesting of the stock options is subject to Paula Ragan's continued service to the board of directors, meaning the options could be forfeited if service ceases before vesting.
• The value of the options is dependent on the future stock price of Camp4 Therapeutics Corp exceeding the exercise price of $1.56.

Future Outlook

The vesting schedule indicates a future commitment from the director, aligning their incentives with the company's long-term performance. The options provide a future potential for the director to acquire shares at a fixed price.

Industry Context

This is a standard compensation practice for directors in publicly traded companies, particularly in the biotechnology or pharmaceutical sector (implied by "Therapeutics Corp"), to align their interests with shareholders. It reflects a common method of non-cash compensation.

Comparison to Industry Standards

• Granting stock options to directors is a common practice across industries, including biotechnology, to incentivize long-term commitment and performance.
• The exercise price of $1.56 suggests the options were granted at or near the market price on the grant date, which is typical for incentive stock options.
• A 10-year expiration period (June 25, 2025, to June 24, 2035) is standard for employee/director stock options, providing a reasonable window for value realization.
• Vesting over one year or until the next annual meeting is also a common structure for director equity grants, ensuring continued service.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases.

Next Steps

• The options will vest on the earlier of June 25, 2026, or the date of the next annual meeting of stockholders, subject to continued service.
• The options can be exercised at any time after vesting until their expiration on June 24, 2035.

Key Dates

Recommendation

Keywords

Camp4 Therapeutics, CAMP, Stock Options, Director Compensation, SEC Form 4, Insider Trading, Equity Grant, Vesting, Biotechnology, Pharmaceuticals